CY1123462T1 - Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων - Google Patents

Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων

Info

Publication number
CY1123462T1
CY1123462T1 CY20201100795T CY201100795T CY1123462T1 CY 1123462 T1 CY1123462 T1 CY 1123462T1 CY 20201100795 T CY20201100795 T CY 20201100795T CY 201100795 T CY201100795 T CY 201100795T CY 1123462 T1 CY1123462 T1 CY 1123462T1
Authority
CY
Cyprus
Prior art keywords
antibodies
hepatitis
virus
relates
antigen
Prior art date
Application number
CY20201100795T
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed S.A. filed Critical Humabs Biomed S.A.
Publication of CY1123462T1 publication Critical patent/CY1123462T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus

Abstract

Η παρούσα εφεύρεση σχετίζεται με αντισώματα, και θραύσματα σύνδεσης με αντιγόνα αυτών, που συνδέονται με την περιοχή αντιγονικού βρόχου του επιφανειακού αντιγόνου της ηπατίτιδας Β (HBsAg) και εξουδετερώνουν ισχυρά τη μόλυνση τόσο από ιό ηπατίτιδας Β (HBV) όσο και από ιό ηπατίτιδας δέλτα (HDV). Η εφεύρεση επίσης σχετίζεται με επιτόπους με τους οποίους συνδέονται τα αντισώματα και θραύσματα σύνδεσης με αντιγόνα, όπως επίσης και με νουκλεϊνικά οξέα που κωδικοποιούν και κύτταρα που παράγουν τέτοια αντισώματα και θραύσματα αντισωμάτων. Επιπλέον, η εφεύρεση σχετίζεται με τη χρήση των αντισωμάτων και θραυσμάτων αντισωμάτων της εφεύρεσης για διάγνωση, πρόληψη και θεραπεία της ηπατίτιδας Β και της ηπατίτιδας D.
CY20201100795T 2015-10-07 2020-08-26 Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων CY1123462T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/001970 WO2017059878A1 (en) 2015-10-07 2015-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof
PCT/EP2016/074114 WO2017060504A1 (en) 2015-10-07 2016-10-07 Antibodies that potently neutralize hepatitis b virus and uses thereof

Publications (1)

Publication Number Publication Date
CY1123462T1 true CY1123462T1 (el) 2022-03-24

Family

ID=54330711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100795T CY1123462T1 (el) 2015-10-07 2020-08-26 Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων

Country Status (25)

Country Link
US (3) US10683344B2 (el)
EP (2) EP3359564B1 (el)
JP (3) JP6869968B2 (el)
KR (1) KR20180056777A (el)
CN (3) CN108137675B (el)
AU (1) AU2016334735B2 (el)
BR (1) BR112018002406A2 (el)
CA (1) CA2993745A1 (el)
CY (1) CY1123462T1 (el)
DK (1) DK3359564T3 (el)
EA (1) EA038301B1 (el)
ES (1) ES2813927T3 (el)
HK (1) HK1256869A1 (el)
HR (1) HRP20201345T1 (el)
HU (1) HUE050231T2 (el)
IL (1) IL258326B (el)
LT (1) LT3359564T (el)
MX (1) MX2018004127A (el)
MY (1) MY187161A (el)
PH (1) PH12018500199A1 (el)
PL (1) PL3359564T3 (el)
PT (1) PT3359564T (el)
SI (1) SI3359564T1 (el)
WO (2) WO2017059878A1 (el)
ZA (1) ZA201800710B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
US11773141B2 (en) 2018-05-10 2023-10-03 Clearb Therapeutics Ltd. Methods and compositions for the treatment of hepatitis B infection
EP3793603A4 (en) * 2018-05-16 2022-01-26 Chang Gung Memorial Hospital, Linkou NEW LRRN1 (LEUCINE-RICH REPEAT NEURONAL PROTEIN 1) ANTIBODIES AND THEIR USES
WO2019229699A1 (en) 2018-05-31 2019-12-05 Novartis Ag Hepatitis b antibodies
LT3898668T (lt) * 2018-12-19 2023-11-10 Humabs Biomed Sa Antikūnai, neutralizuojantys hepatito b virusą ir jų panaudojimas
HRP20231338T1 (hr) * 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Kombinirana terapija hbv
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
US20220259292A1 (en) * 2019-07-20 2022-08-18 Huahui Health Ltd. A method of treating hbv infection by using anti-pre-s1 hbv antibodies
MX2022002231A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
KR20230042023A (ko) 2020-06-24 2023-03-27 비르 바이오테크놀로지, 인코포레이티드 조작된 b형 간염 바이러스 중화 항체 및 이의 용도
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
CN113234144B (zh) * 2021-05-26 2022-02-25 武汉工程大学 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
WO2023122555A2 (en) * 2021-12-21 2023-06-29 Hbvtech, Llc. Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
CN116162153A (zh) * 2022-09-01 2023-05-26 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1997039029A2 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
AU736032B2 (en) * 1996-12-30 2001-07-26 Innogenetics N.V. Annexin V-binding polypeptides derived from HBsAg and their uses
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1848740A1 (en) * 2005-01-14 2007-10-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Monoclonal antibodies that bind or neutralize hepatitis b virus
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
WO2010046775A2 (en) 2008-10-22 2010-04-29 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
SG11201501255PA (en) * 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
CN104955837A (zh) * 2012-11-12 2015-09-30 海德堡吕布莱希特-卡尔斯大学 Hbv和/或hdv易感细胞、细胞系和非人动物的开发
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
SI3359564T1 (sl) 2020-10-30
JP7171809B2 (ja) 2022-11-15
PH12018500199A1 (en) 2018-08-13
US11390664B2 (en) 2022-07-19
EA038301B1 (ru) 2021-08-06
CN114539392B (zh) 2024-01-26
KR20180056777A (ko) 2018-05-29
ES2813927T3 (es) 2021-03-25
HRP20201345T1 (hr) 2020-11-27
AU2016334735B2 (en) 2022-10-27
CN114539391A (zh) 2022-05-27
EP3359564A1 (en) 2018-08-15
CN108137675B (zh) 2022-03-22
JP6869968B2 (ja) 2021-05-12
JP2023011809A (ja) 2023-01-24
JP2021121188A (ja) 2021-08-26
US20210040183A1 (en) 2021-02-11
IL258326A (en) 2018-05-31
DK3359564T3 (da) 2020-08-17
PT3359564T (pt) 2020-09-04
WO2017060504A1 (en) 2017-04-13
ZA201800710B (en) 2019-05-29
EP3753949A1 (en) 2020-12-23
MX2018004127A (es) 2018-06-13
US20230303663A1 (en) 2023-09-28
CN108137675A (zh) 2018-06-08
JP2018535650A (ja) 2018-12-06
CN114539392A (zh) 2022-05-27
PL3359564T3 (pl) 2020-11-30
EP3359564B1 (en) 2020-06-03
BR112018002406A2 (pt) 2018-09-18
US20190016785A1 (en) 2019-01-17
IL258326B (en) 2021-10-31
MY187161A (en) 2021-09-06
AU2016334735A1 (en) 2018-02-15
US10683344B2 (en) 2020-06-16
HUE050231T2 (hu) 2020-11-30
WO2017059878A1 (en) 2017-04-13
EA201890874A1 (ru) 2018-11-30
CA2993745A1 (en) 2017-04-13
HK1256869A1 (zh) 2019-10-04
LT3359564T (lt) 2020-10-26

Similar Documents

Publication Publication Date Title
CY1123462T1 (el) Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων
PH12018502348A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123068T1 (el) Εξουδετερωτικα αnτισωματα εναντι gp120 και χρηση αυτων
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CY1124979T1 (el) Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
EA200900033A1 (ru) Вакцины против малярии
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
SG10201806025TA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
WO2014128568A3 (en) Compositions and methods for treatment of hepatitis c
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
EA202191706A1 (ru) Антитела, нейтрализирующие вирус гепатита в, и их применение
EA201891048A1 (ru) Антитело, нейтрализующее респираторно-синцитиальный вирус человека
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
WO2015128731A3 (en) Compositions and methods for treatment of hepatitis c